China – Page 2 – Talk Bio

Sanofi Acquires China Rights to Arrowhead’s Plozasiran for $395 Million

4 months ago talkbio0Tagged Arrowhead, China, Familial chylomicronemia syndrome, Hypertriglyceridemia, milestone payments, Partnership, Plozasiran, RNA Interference, sanofi, Severe (severity modifier)

Sanofi; Arrowhead Pharmaceuticals; Visirna Therapeutics; Plozasiran; China rights; RNA interference; Familial chylomicronemia syndrome; Severe hypertriglyceridemia; biotech partnership; milestone payments

Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications

4 months ago talkbio0Tagged China, Clinical Trials, Dosage Forms, Ecosystem, global drug development, Industry, innovation, Legal patent, US-China competition

China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

5 months ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

AstraZeneca and CSPC Enter $5.3B AI-Driven Drug Discovery Pact in China

5 months ago talkbio0Tagged Artificial Intelligence, AstraZeneca, China, Chronic disease, Dosage Forms, Drug Discovery, GZMH gene, Investments, oral therapies, Partnership, R&D, research

AstraZeneca; CSPC Pharmaceutical; AI research; drug discovery; chronic diseases; China; $5.3 billion; oral therapies; partnership; R&D investment

Biotech Leaders Urge FDA to ‘Modernise’ Regulation to Compete with China

6 months ago talkbio0Tagged Cells, CEO, China, competitiveness, gene therapy, innovation, Modernization, Regulation, roundtable, United States Food and Drug Administration

FDA; biotech; regulation; modernization; China; cell and gene therapy; CEO roundtable; competitiveness; innovation

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

6 months ago talkbio0Tagged Cancer Therapeutic Procedure, China, Drug Development, Licensing Deal, Neoplasms, PD-1/VEGF bispecific antibody, Pfizer, SSGJ-707, upfront payment

Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development

Roche Pledges Nearly $300M to Establish New Vabysmo Production Plant in China

6 months ago talkbio0Tagged Biopharmaceutical manufacturing, China, Disorder of eye, green energy, Investments, localization, plant construction, Roche (company), Shanghai, Vabysmo

Roche; Vabysmo; biopharmaceutical manufacturing; Shanghai; China; investment; eye disease treatment; plant construction; localization; green energy

AstraZeneca’s China woes recede as focus shifts to upcoming readouts

7 months ago talkbio0Tagged Acquisition, Beijing, biotech, China, China legal issues resolution, FibroGen, Fine - adjective, global strategic R&D center, Investments, Manufacturing, partnerships, R&D

$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition